MCID: CLR023
MIFTS: 95

Colorectal Cancer

Categories: Genetic diseases, Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Colorectal Cancer

MalaCards integrated aliases for Colorectal Cancer:

Name: Colorectal Cancer 54 38 12 24 24 71 29 13 13 52 41 14 69
Colon Cancer 54 12 24 71 29 52 14
Colon Carcinoma 12 24 52 14 69
Colorectal Cancer, Somatic 54 24 13
Colon Cancer, Somatic 54 13
Colorectal Carcinoma 52 69
Colorectal Neoplasms 42 69
Carcinoma of Colon 12 29
Colonic Neoplasms 42 69
Crc 24 71
Colonic Adenoma Recurrence, Reduced Risk of 54
Colon Cancer, Advanced, Somatic 54
Colon Cancer, Advanced Somatic 24
Malignant Tumor of Colon 69
Colonic Carcinoma 12

Characteristics:

OMIM:

54
Inheritance:
autosomal dominantly acting oncogene plus loss of suppressor gene(s)


Classifications:



Summaries for Colorectal Cancer

MedlinePlus : 41 the colon and rectum are part of the large intestine. colorectal cancer occurs when tumors form in the lining of the large intestine. it is common in both men and women. the risk of developing colorectal cancer rises after age 50. you're also more likely to get it if you have colorectal polyps, a family history of colorectal cancer, ulcerative colitis or crohn's disease, eat a diet high in fat, or smoke. symptoms of colorectal cancer include diarrhea or constipation a feeling that your bowel does not empty completely blood (either bright red or very dark) in your stool stools that are narrower than usual frequent gas pains or cramps, or feeling full or bloated weight loss with no known reason fatigue nausea or vomiting because you may not have symptoms at first, it's important to have screening tests. everyone over 50 should get screened. tests include colonoscopy and tests for blood in the stool. treatments for colorectal cancer include surgery, chemotherapy, radiation, or a combination. surgery can usually cure it when it is found early. nih: national cancer institute

MalaCards based summary : Colorectal Cancer, also known as colon cancer, is related to mismatch repair cancer syndrome and hepatocellular carcinoma, and has symptoms including hereditary nonpolyposis colorectal carcinoma, uterine leiomyosarcoma and transitional cell carcinoma of the bladder. An important gene associated with Colorectal Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Colorectal cancer and Ras signaling pathway. The drugs Avastin and Campostar have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and testes, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

UniProtKB/Swiss-Prot : 71 Colorectal cancer: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

OMIM : 54
Colorectal cancer is a heterogeneous disease that is common in both men and women. In addition to lifestyle and environmental risk factors, gene defects can contribute to an inherited predisposition to CRC. CRC is caused by changes in different molecular pathogenic pathways, such as chromosomal instability, CpG island methylator phenotype, and microsatellite instability. Chromosome instability is the most common alteration and is present in almost 85% of all cases (review by Schweiger et al., 2013). (114500)

Disease Ontology : 12 A large intestine cancer that is located in the colon and/or located in the rectum.

Wikipedia : 72 Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from... more...

Related Diseases for Colorectal Cancer

Diseases in the Colorectal Cancer family:

Colorectal Cancer 6 Colorectal Cancer 2
Colorectal Cancer 1 Colorectal Cancer 5
Colorectal Cancer 7 Colorectal Cancer 12
Colorectal Cancer 8 Colorectal Cancer 9
Colorectal Cancer 3 Colorectal Cancer 10
Colorectal Cancer 11 Familial Colorectal Cancer
Hereditary Colorectal Cancer Familial Colorectal Cancer Type X

Diseases related to Colorectal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
id Related Disease Score Top Affiliating Genes
1 mismatch repair cancer syndrome 33.8 APC CTNNB1 MLH1
2 hepatocellular carcinoma 32.5 APC BAX CTNNB1 DLC1 PDGFRL PIK3CA
3 lung cancer 32.4 BAX BRAF CTNNB1 FGFR3 MLH1 PIK3CA
4 atrophic gastritis 32.0 BRAF MLH1 TP53
5 colorectal cancer, hereditary nonpolyposis, type 1 12.3
6 colorectal cancer 1 12.3
7 colorectal cancer, hereditary nonpolyposis, type 5 12.3
8 colorectal cancer 3 12.2
9 colorectal cancer 10 12.2
10 colorectal cancer, hereditary nonpolyposis, type 6 12.2
11 colorectal cancer, hereditary nonpolyposis, type 4 12.2
12 colorectal cancer, hereditary nonpolyposis, type 2 12.2
13 colorectal cancer, hereditary nonpolyposis, type 7 12.2
14 colorectal cancer, hereditary nonpolyposis, type 8 12.2
15 oligodontia-colorectal cancer syndrome 12.2
16 colorectal cancer 12 12.2
17 macrocytic anemia 12.1 APC AXIN2 BAX BRAF CTNNB1 DCC
18 familial colorectal cancer 12.1
19 lethal congenital contracture syndrome 10 12.1 BAX BRAF CTNNB1 MLH1 MLH3 PIK3CA
20 systemic lupus erythematosus with nephritis 2 12.1 APC AXIN2 BAX CTNNB1 EP300 MLH1
21 adenosquamous colon carcinoma 12.1
22 colorectal cancer 2 12.0
23 colorectal cancer 5 12.0
24 medullary colon carcinoma 12.0
25 transverse colon cancer 12.0
26 ascending colon cancer 12.0
27 colon carcinoma in situ 12.0
28 arrhythmogenic right ventricular cardiomyopathy 12.0 APC AXIN2 CTNNB1 MCC MLH1 TP53
29 descending colon cancer 12.0
30 childhood optic nerve glioma 12.0 APC AXIN2 BRAF CTNNB1 MLH1 TP53
31 hereditary colorectal cancer 12.0
32 gastric cancer, somatic 12.0 APC BAX CTNNB1 MLH1 PIK3CA TP53
33 familial colorectal cancer type x 12.0
34 gastric fundus cancer 11.9 APC CTNNB1 MLH1 PIK3CA SRC TP53
35 lynch syndrome 11.9
36 colorectal cancer 8 11.9
37 apocrine adenoma 11.9 APC BRAF MLH1 MLH3 TP53
38 colorectal cancer 6 11.9
39 colorectal cancer 9 11.9
40 colorectal cancer, childhood 11.9
41 colorectal cancer 7 11.9
42 colorectal cancer 11 11.9
43 chek2-related susceptibility to breast and colorectal cancer 11.8
44 colorectal cancer susceptibility 10 11.8
45 selection of therapeutic option in colorectal cancer 11.8
46 colorectal cancer susceptibility 12 11.8
47 nail disorder, nonsyndromic congenital, 3, 11.8 BAX CTNNB1 DCC PIK3CA TP53
48 sertoli-leydig cell tumor 11.8 BRAF CTNNB1 FGFR3 MLH1 TP53
49 glycogen storage disease due to lactate dehydrogenase deficiency 11.8 CTNNB1 PDGFRL PIK3CA TP53
50 maxillary neoplasm 11.8 APC CTNNB1 MLH1 TP53

Comorbidity relations with Colorectal Cancer via Phenotypic Disease Network (PDN): (show all 22)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Ascending Colon Cancer
Cecal Benign Neoplasm Deficiency Anemia
Descending Colon Cancer Familial Atrial Fibrillation
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Intestinal Obstruction
Intestinal Perforation Iron Deficiency Anemia
Neutropenia Paralytic Ileus
Protein-Energy Malnutrition Rectal Neoplasm
Rectosigmoid Junction Neoplasm Small Intestine Cancer
Splenic Flexure Cancer Transverse Colon Cancer

Graphical network of the top 20 diseases related to Colorectal Cancer:



Diseases related to Colorectal Cancer

Symptoms & Phenotypes for Colorectal Cancer

Symptoms via clinical synopsis from OMIM:

54

Oncology:
hereditary nonpolyposis colorectal carcinoma
associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma
apc, ras, dcc or kras gene mutations
allele loss on chromosomes 5, 6, 12q, 15, 17, 18, or 22


Clinical features from OMIM:

114500

Human phenotypes related to Colorectal Cancer:

32
id Description HPO Frequency HPO Source Accession
1 hereditary nonpolyposis colorectal carcinoma 32 HP:0006716
2 uterine leiomyosarcoma 32 HP:0002891
3 transitional cell carcinoma of the bladder 32 HP:0006740
4 renal cell carcinoma 32 HP:0005584
5 neoplasm of the stomach 32 HP:0006753

UMLS symptoms related to Colorectal Cancer:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

GenomeRNAi Phenotypes related to Colorectal Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.5 TP53 BAX BRAF EP300 MLH1 MLH3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 BAX DCC MLH1 PDGFRL RAD54B TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 BAX BRAF DCC MLH1 PDGFRL RAD54B

MGI Mouse Phenotypes related to Colorectal Cancer:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 APC AXIN2 BAX BRAF CTNNB1 DCC
2 mortality/aging MP:0010768 10.44 MLH1 PIK3CA PTPN12 PTPRJ RAD54B SRC
3 growth/size/body region MP:0005378 10.42 APC AXIN2 BAX BRAF CTNNB1 DLC1
4 hematopoietic system MP:0005397 10.4 RAD54B SRC TP53 APC BAX BRAF
5 embryo MP:0005380 10.37 APC AXIN2 BRAF CTNNB1 DLC1 EP300
6 cardiovascular system MP:0005385 10.36 FLCN PIK3CA PTPN12 PTPRJ TP53 APC
7 homeostasis/metabolism MP:0005376 10.36 APC MLH1 BAX PIK3CA BRAF PTPRJ
8 immune system MP:0005387 10.35 BRAF CTNNB1 DCC EP300 FGFR3 FLCN
9 endocrine/exocrine gland MP:0005379 10.32 EP300 MLH1 MLH3 PIK3CA SRC TP53
10 neoplasm MP:0002006 10.29 FGFR3 FLCN MLH1 PIK3CA PTPRJ SRC
11 nervous system MP:0003631 10.27 APC AXIN2 BAX BRAF CTNNB1 DCC
12 craniofacial MP:0005382 10.26 SRC TP53 CTNNB1 DLC1 EP300 FGFR3
13 digestive/alimentary MP:0005381 10.2 CTNNB1 DCC EP300 FGFR3 MLH1 TP53
14 muscle MP:0005369 10.1 APC BAX BRAF CTNNB1 EP300 PIK3CA
15 normal MP:0002873 10.1 CTNNB1 DLC1 EP300 FGFR3 MCC PTPRJ
16 limbs/digits/tail MP:0005371 10.07 APC AXIN2 BAX CTNNB1 FGFR3 SRC
17 hearing/vestibular/ear MP:0005377 10.04 APC BAX BRAF CTNNB1 FGFR3 TP53
18 no phenotypic analysis MP:0003012 10.03 APC AXIN2 CTNNB1 FGFR3 PIK3CA PTPN12
19 reproductive system MP:0005389 10.03 APC AXIN2 BAX BRAF CTNNB1 FGFR3
20 renal/urinary system MP:0005367 9.92 APC BAX BRAF CTNNB1 EP300 FGFR3
21 pigmentation MP:0001186 9.85 APC BRAF CTNNB1 DCC SRC TP53
22 respiratory system MP:0005388 9.85 BAX BRAF CTNNB1 DCC EP300 FGFR3
23 skeleton MP:0005390 9.61 BAX BRAF CTNNB1 FGFR3 PIK3CA SRC
24 vision/eye MP:0005391 9.4 APC AXIN2 BAX BRAF CTNNB1 DCC

Drugs & Therapeutics for Colorectal Cancer

FDA approved drugs:

(show all 12)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Avastin 17 46 BEVACIZUMAB Genentech July 2009
2
Campostar 17 46 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
3
CEA-Scan 17 Immunomedics April 1996
4
Eloxatin 17 46 OXALIPLATIN Sanofi-aventis August 2002
5
Erbitux 17 46 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
6
Fusilev 17 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
7
Iressa 17 46 GEFITINIB AstraZeneca May 2003
8
Stivarga 17 46 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
9
Sutent 17 46 SUNITINIB MALATE Pfizer May 2011/ January 2006
10
Vectibix 17 46 PANITUMUMAB Amgen September 2006
11
Xeloda 17 46 CAPECITABINE Roche April 1998/ May 2001
12
Zaltrap 17 46 ZIV-AFLIBERCEPT Sanofi-aventis August 2012

Drugs for Colorectal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 855)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-21-8 3385
2
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
3
Tegafur Approved Phase 4,Phase 3,Phase 1,Phase 2 17902-23-7 5386
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
5
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
6
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
7
Levoleucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
8
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
9
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
10
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 137-58-6 3676
11
Erythromycin Approved, Vet_approved Phase 4,Phase 2 114-07-8 12560
12
Bisacodyl Approved Phase 4 603-50-9
13
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
14
Benzocaine Approved Phase 4,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
15
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
16
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
17
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
18
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 71273 175805
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Early Phase 1 437-38-7 3345
20
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112887-68-0 104758
21
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
22
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1 2216-51-5 16666
23
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
24
Propofol Approved, Investigational, Vet_approved Phase 4,Early Phase 1 2078-54-8 4943
25
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
26
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
27
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2 53-86-1 3715
28
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
29 Magnesium citrate Approved Phase 4,Phase 3
30
Udenafil Approved, Investigational Phase 4,Phase 2 268203-93-6 6918523
31
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
32
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2 83150-76-9 383414 6400441
33
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
34
Magnesium oxide Approved Phase 4,Phase 2 1309-48-4 14792
35
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
36
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
37
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
38
Guaifenesin Approved, Vet_approved Phase 4,Phase 2 93-14-1 3516
39
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
40
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 1 76-42-6 5284603
41
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
42
Sevoflurane Approved, Vet_approved Phase 4,Early Phase 1 28523-86-6 5206
43
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
44
Ethiodized oil Approved Phase 4,Phase 2 8008-53-5
45
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
46
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
47
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
48
Acetaminophen Approved Phase 4 103-90-2 1983
49
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
50
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570

Interventional clinical trials:

(show top 50) (show all 4582)

id Name Status NCT ID Phase Drugs
1 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
2 Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
3 Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01972490 Phase 4 avastin+chemotherapy of mFOLFOX6 or FOLFIRI;chemotherapy of mFOLFOX6 or FOLFIRI
4 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
5 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
6 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
7 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
8 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
9 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
10 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
11 Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
12 Preoperative Assessment of Colon Tumor Unknown status NCT00114829 Phase 4
13 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
14 Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
15 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
16 Trial on Mechanical Bowel Preparation in Laparoscopic Colorectal Surgery Unknown status NCT01797770 Phase 4 polyethylene glycol
17 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
18 Dissemination of Colorectal Cancer Screening to Primary Care Physicians Completed NCT00441311 Phase 4
19 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
20 Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients Completed NCT01732783 Phase 4
21 Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles Completed NCT00868816 Phase 4 12 cycles of oxaliplatine based adjuvant chemotherapy;8 cycles of oxaliplatine based adjuvant chemotherapy
22 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Completed NCT01588990 Phase 4 Oxaliplatin;Capecitabine;Bevacizumab;Leucovorin;5-Fluouracil;Irinotecan
23 Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer Completed NCT00928928 Phase 4
24 Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer Completed NCT00869271 Phase 4
25 Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population Completed NCT01557101 Phase 4
26 Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients Completed NCT00473980 Phase 4 Indomethacin, celecoxib, esomeprazole
27 A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer Completed NCT02567331 Phase 4 Capecitabine
28 Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
29 A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer Completed NCT01695772 Phase 4 5-FU based doublet chemotherapy;bevacizumab
30 The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery Completed NCT00122720 Phase 4 Darbepoetin Alfa
31 CHOICE: Communicating Health Options Through Information and Cancer Education Completed NCT00134589 Phase 4
32 I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer Completed NCT00677586 Phase 4
33 A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) Completed NCT00388206 Phase 4
34 Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants Completed NCT00138060 Phase 4 irinotecan;5 fluorouracil
35 Nutrition for Colorectal Cancer Patients and Neutrophil Functions Completed NCT01831310 Phase 4
36 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
37 Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients Completed NCT01641458 Phase 4
38 Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery Completed NCT00488904 Phase 4
39 Health Economic Evaluation of Primovist-enhanced Liver MRI Completed NCT00764621 Phase 4
40 A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma Completed NCT00097578 Phase 4
41 Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT) Completed NCT01607255 Phase 4 Indigo carmine
42 Trial of Patient Navigation-Activation Completed NCT00496678 Phase 4
43 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
44 Preoperative Assessment for Synchronous Carcinoma or Polyps With Magnetic Resonance (MR) Colonography Completed NCT00300547 Phase 4
45 Inflammatory Response in Laparoscopic and Open Colectomy Completed NCT00942461 Phase 4
46 A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer Completed NCT02581423 Phase 4 Capecitabine
47 Impact of Probiotics on the Intestinal Microbiota Completed NCT01609660 Phase 4
48 A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
49 Comparison of Two Methods of Administration of a PEG Solution Completed NCT00626054 Phase 4 PEG solution in a single dose of 3 liters;PEG solution
50 A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer. Completed NCT00502671 Phase 4 capecitabine [Xeloda]

Search NIH Clinical Center for Colorectal Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Colorectal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Colorectal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Colorectal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: colonic neoplasms

Genetic Tests for Colorectal Cancer

Genetic tests related to Colorectal Cancer:

id Genetic test Affiliating Genes
1 Carcinoma of Colon 29
2 Colon Cancer 29
3 Colorectal Cancer 29 24 TP53
4 Colorectal Cancer, Somatic 24 CTNNB1 DCC FGFR3 EP300 BRAF FLCN NRAS
5 Colon Cancer, Advanced Somatic 24 SRC
6 Colon Cancer (apc I1307k Related) 24 APC

Anatomical Context for Colorectal Cancer

MalaCards organs/tissues related to Colorectal Cancer:

39
Colon, Liver, Testes, Lung, Lymph Node, Endothelial, Prostate

Publications for Colorectal Cancer

Articles related to Colorectal Cancer:

(show top 50) (show all 10569)
id Title Authors Year
1
TGF-I^1 induces PGP9.5 expression in CAFs to promote the growth of colorectal cancer cells. ( 27840994 )
2017
2
p53/microRNA-374b/AKT1 regulates colorectal cancer cell apoptosis in response to DNA damage. ( 28339062 )
2017
3
Suppression subtractive hybridization identified differentially expressed genes in colorectal cancer: microRNA-451a as a novel colorectal cancer-related gene. ( 28468585 )
2017
4
Profile of Expression of Genes Encoding Matrix Metallopeptidase 9 (MMP9), Matrix Metallopeptidase 28 (MMP28) and TIMP Metallopeptidase Inhibitor 1 (TIMP1) in Colorectal Cancer: Assessment of the Role in Diagnosis and Prognostication. ( 28293015 )
2017
5
Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. ( 28092401 )
2017
6
The prognostic value of p53 positive in colorectal cancer: A retrospective cohort study. ( 28468582 )
2017
7
LncRNA PlncRNA-1 Promotes Colorectal Cancer Cell Progression by Regulating PI3K/Akt Signaling Pathway. ( 28835319 )
2017
8
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. ( 28950295 )
2017
9
Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1). ( 28667355 )
2017
10
Thioredoxin-1 promotes colorectal cancer invasion and metastasis through crosstalk with S100P. ( 28483515 )
2017
11
Pomegranate By-Products in Colorectal Cancer Chemoprevention: Effects in Apc-Mutated Pirc Rats and Mechanistic Studies in vitro and ex vivo. ( 28948694 )
2017
12
miR-133a acts as a tumor suppressor in colorectal cancer by targeting eIF4A1. ( 28466778 )
2017
13
Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer. ( 28259994 )
2017
14
Study on the Relation between Colorectal Cancer and Gall Bladder Disease. ( 28511430 )
2017
15
Resveratrol Regulates Colorectal Cancer Cell Invasion by Modulation of Focal Adhesion Molecules. ( 28953264 )
2017
16
Identification of MSX1 and DCLK1 as mRNA Biomarkers for Colorectal Cancer Detection Through DNA Methylation Information. ( 27966796 )
2017
17
MFG-E8 overexpression promotes colorectal cancer progression via AKT/MMPs signalling. ( 28653875 )
2017
18
Expression pattern of miR-451 and its target MIF (macrophage migration inhibitory factor) in colorectal cancer. ( 27612504 )
2017
19
Molecular basis of gut microbiome-associated colorectal cancer: A synthetic perspective. ( 28949546 )
2017
20
Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial. ( 28089385 )
2017
21
miR-4775 promotes colorectal cancer invasion and metastasis via the Smad7/TGFI^-mediated epithelial to mesenchymal transition. ( 28095858 )
2017
22
Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer. ( 28423402 )
2017
23
Up-Regulated Expression of SPRY4-IT1 Predicts Poor Prognosis in Colorectal Cancer. ( 28099409 )
2017
24
KIF11 Is Required for Spheroid Formation by Oesophageal and Colorectal Cancer Cells. ( 28011472 )
2017
25
Role of CDH13 promoter methylation in the carcinogenesis, progression, and prognosis of colorectal cancer: A systematic meta-analysis under PRISMA guidelines. ( 28121942 )
2017
26
SAV1 represses the development of human colorectal cancer by regulating the Akt-mTOR pathway in a YAP-dependent manner. ( 28618450 )
2017
27
Screening of BMPR1a for pathogenic mutations in familial colorectal cancer type X families from Newfoundland. ( 28660566 )
2017
28
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. ( 28347919 )
2017
29
Tumor-suppressive role of Kruppel-like factor 4 (KLF-4) in colorectal cancer. ( 28218782 )
2017
30
Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients. ( 28306719 )
2017
31
Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. ( 28044229 )
2017
32
MicroRNA-141 inhibits tumor growth and minimizes therapy resistance in colorectal cancer. ( 28112364 )
2017
33
The loss-of-function mutations and down-regulated expression of ASB3 gene promote the growth and metastasis of colorectal cancer cells. ( 28088228 )
2017
34
HRG/HER2/HER3 signaling promotes AhR-mediated Memo-1 expression and migration in colorectal cancer. ( 27941874 )
2017
35
Association of a novel genetic variant in RP11-650L12.2 with risk of colorectal cancer in Han Chinese population. ( 28442398 )
2017
36
Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability. ( 27620344 )
2017
37
Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. ( 28947960 )
2017
38
Differential expression of ST6GAL1 in the tumor progression of colorectal cancer. ( 28377225 )
2017
39
Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer. ( 28953975 )
2017
40
The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study. ( 28618945 )
2017
41
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. ( 28403223 )
2017
42
Low Variability and Stable Frequency of Common Haplotypes of the TP53 Gene Region in Colorectal Cancer Patients in a Slovak Population. ( 28373458 )
2017
43
A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with Raltitrexed. ( 28535418 )
2017
44
SN38-PEG-PLGA-verapamil nanoparticles inhibit proliferation and downregulate drug transporter ABCG2 gene expression in colorectal cancer cells. ( 28948511 )
2017
45
Perceived Stress and Colorectal Cancer Incidence: The Japan Collaborative Cohort Study. ( 28091607 )
2017
46
Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. ( 28368335 )
2017
47
Expression of claudin 1, claudin 4, and claudin 7 in colorectal cancer and its relation with CLDN DNA methylation patterns. ( 28381183 )
2017
48
DDR2 Expression Is Associated with a High Frequency of Peritoneal Dissemination and Poor Prognosis in Colorectal Cancer. ( 28476831 )
2017
49
CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study. ( 28087988 )
2017
50
Decoupling of DNA methylation and activity of intergenic LINE-1 promoters in colorectal cancer. ( 28300471 )
2017